Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07690371 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
A Phase 3 study, sponsored by Nektar Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
NCT07690371: Recruiting Phase 3 study, sponsored by Nektar Therapeutics.
NCT07690371 is a Phase 3 study that is actively recruiting participants, run by Nektar Therapeutics. The registered enrollment target is 510 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07690371, a Phase 3 study, is actively recruiting participants, sponsored by Nektar Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
Study Summary
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.
Primary Outcome
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
Interventions
- DRUG Placebo
- DRUG Rezpegaldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT07690371 shows while recruiting
NCT07690371 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07690371 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07690371 about?
NCT07690371 is a clinical study titled "A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis". This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approxima...
What is the current status of trial NCT07690371?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2026-07. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07690371?
The interventions under investigation include: Placebo (DRUG), Rezpegaldesleukin (DRUG).
Who is sponsoring clinical trial NCT07690371?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07690371's enrollment target sits among peer trials
510 729th of 2000 higher than 1,264 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia